Captain T Cell GmbH, a biotech company focused on next-generation T cells for solid tumors, has successfully closed a €8.5 million seed financing round.
The investment was led by i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H, with support from the German Federal Ministry of Education and Research (BMBF) through its GO-Bio program. The funds will advance Captain T Cell’s lead program and novel allogeneic TCR-ALLO platform for off-the-shelf solid tumor treatments.
Captain T Cell’s first-in-class TCR-T cells show enhanced persistence and tumor microenvironment adaptability. Preclinical models have demonstrated complete tumor eradication. The company, spun off from the Max Delbrück Center in Berlin, leverages next-gen technologies for challenging tumor therapies.
Do you need investors for your startup?
Dr. Felix Lorenz, CEO, highlighted the financing’s role in accelerating high-potential therapies. Dr. Jaromir Zahrádka of i&i Bio praised the team’s preclinical data and off-the-shelf approach’s cost-effectiveness. Hao Nam Nguyen of Brandenburg Kapital and Dr. Friedrich Hillebrand of HIL-INVENT emphasized the company’s potential in addressing unmet medical needs in aggressive solid tumors.
Jörn Aldag has been appointed Chairman of the Board, bringing biotech expertise to guide Captain T Cell’s mission to become a leader in novel oncology drugs.
To read full article / source click here
* It is a community posted article. Please read the Full Disclaimer below
Disclaimer: This post is AI-generated. Its content does not represent the views of Xstartups. Xstartups is not liable for the accuracy or implications of the content. For any concerns or copyright issue, contact us at complaint@xstartups.co.
